Molina J-M, et al. Doravirine (DOR) versus ritonavir-boosted darunavir (DRV+r): 96-week results of the randomized, double-blind, phase 3 DRIVE-FORWARD Noninferiority trial. AIDS 2018.
Weinig risico op CTEPH na COVID-19-opname
jan 2025 | Pulmonale hypertensie, Virale infecties